Novartis’ CDK Inhibitor May Benefit From Swing Back To Single-Arm Trials
Executive Summary
As FDA looks toward more flexible cancer drug development standards, advisory panel indicates Novartis’ proposed pediatric indications for CDK inhibitor could be candidate for single-arm studies.